Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women.
- DOI
- 10.1002/cpdd.968
- Published
- 2021-06-08
- Container
- Clin Pharmacol Drug Dev
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cpdd.968,
title = {Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women.},
author = {Donath F and Hoffmann L and Todorova-Sanjari M and Wedemeyer RS and Warnke A and Nickisch K.},
year = {2022},
journal = {Clin Pharmacol Drug Dev},
doi = {10.1002/cpdd.968},
url = {https://doi.org/10.1002/cpdd.968}
}RIS
TY - JOUR TI - Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. AU - Donath F AU - Hoffmann L AU - Todorova-Sanjari M AU - Wedemeyer RS AU - Warnke A AU - Nickisch K. PY - 2022 JO - Clin Pharmacol Drug Dev DO - 10.1002/cpdd.968 UR - https://doi.org/10.1002/cpdd.968 ER -
APA
F, D., L, H., M, T., RS, W., A, W., & K., N. (2022). Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women.. Clin Pharmacol Drug Dev. https://doi.org/10.1002/cpdd.968
Source records
- europe-pmc · retrieved 2026-09-26T18:32:49.953Z